Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma
暂无分享,去创建一个
J. Ajani | Randy L. Johnson | W. Hofstetter | A. Correa | Koyu Suzuki | Zhen-ning Wang | J. Estrella | A. Suzuki | Shumei Song | K. Harada | Yan Xu | Xiaochuan Dong | H. Onodera | K. Sudo
[1] R. Birge,et al. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression , 2017, Molecular Cancer Research.
[2] Minghui Zhang,et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients , 2016, Scientific Reports.
[3] A. Mansfield,et al. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non‐Small Cell Lung Cancer to Receive Immunotherapy , 2016, Clinical pharmacology and therapeutics.
[4] J. Lunceford,et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.
[5] Sung Sook Lee,et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. , 2016 .
[6] M. Shimada,et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection , 2016, Gastric Cancer.
[7] H. Kalthoff,et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients , 2016, Oncotarget.
[8] Yoon-Koo Kang,et al. Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. , 2016 .
[9] Y. Jeon,et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. , 2015, European journal of cancer.
[10] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[11] K. Hirakawa,et al. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. , 2015, Anticancer research.
[12] Dajun Yang,et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. , 2015, International journal of clinical and experimental pathology.
[13] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[14] D. Linehan,et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.
[15] T. Aparicio,et al. PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .
[16] Jason G. Jin,et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.
[17] Brian Ruffell,et al. Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.
[18] N. Matsumura,et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.
[19] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[20] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[21] Johann A. Gagnon-Bartsch,et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas , 2014, Gut.
[22] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[23] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[24] J. Blay,et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.
[25] Jing‐ying Hou,et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. , 2014, Experimental and molecular pathology.
[26] David C. Smith,et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Antonia,et al. PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells , 2014, PloS one.
[28] H. Baba,et al. Identification of miR-30e* Regulation of Bmi1 Expression Mediated by Tumor-Associated Macrophages in Gastrointestinal Cancer , 2013, PloS one.
[29] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[30] Yun Feng,et al. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. , 2012, Immunobiology.
[31] R. Schwendener,et al. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors , 2012, BMC Cancer.
[32] Loise M. Francisco,et al. The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.
[33] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[34] Yarong Wang,et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. , 2007, Cancer research.
[35] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Alberto Mantovani,et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.
[37] R. Herbst,et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.
[38] Sang-Hoon Ahn,et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer , 2014, Gastric Cancer.
[39] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[40] C. Balch,et al. AJCC Cancer Staging Manual. 6th ed , 2002 .